How to Prepare Clinical Evaluation Documentation for Overseas Registration of POCT Products

To prepare clinical evaluation documentation for overseas registration of POCT (Point-of-Care Testing) products, manufacturers must first determine whether the product is regulated as a medical device in the target country, identify the risk classification and corresponding registration pathway, and then compile clinical evidence that satisfies local regulatory requirements. Reusing existing clinical data from NMPA, CE, or FDA can reduce redundant work, but supplementary validation for local population, sample types, and operator variability is often necessary. A structured clinical evaluation plan, statistically sound sample sizes, and early engagement with local regulatory representatives are critical to avoiding delays and ensuring approval.

Key Summary

Clinical evaluation documentation is one of the core technical files for overseas registration of POCT products, directly affecting the review timeline and outcome. Companies must first assess whether the target country regulates POCT products as medical devices, then determine the registration route based on risk class. Regulatory requirements for clinical evidence vary significantly across markets: EU CE certification typically requires clinical performance studies under MDR or IVDR, providing data on intended use, analytical performance, clinical sensitivity, and specificity; the US FDA requires clinical evidence in 510(k) or PMA submissions, with substantial equivalence comparisons to legally marketed devices; many GHWP member countries (e.g., Southeast Asia, Middle East, Latin America) accept CE or FDA data, but require local adaptation, including adjustments for applicable populations, epidemiological context, and laboratory environment. Companies should prioritize reusing existing clinical data from NMPA, CE, or FDA, while supplementing validation for local variables such as subpopulations, sample types, and operator differences. Common risks include failure to assess local clinical environment deviations, insufficient sample size in performance studies, lack of repeatability and reproducibility data, and missing consistency analysis between intended use claims and clinical evidence. It is recommended to establish a cross-functional team early, define the registration sequence for target markets, prioritize core clinical evidence preparation, and appoint local agents to facilitate review communication.

Applicable Scenarios and Core Questions

POCT products are widely used in emergency care, primary healthcare, and home self-testing due to their rapid and convenient characteristics. During overseas registration, clinical evaluation documentation is a critical file for demonstrating safety and effectiveness, directly influencing regulatory decisions.

Different regulatory bodies have significantly different requirements for clinical evidence. The EU IVDR requires clinical performance studies (including analytical performance, clinical sensitivity, specificity, positive predictive value, etc.). The US FDA typically requires substantial equivalence comparison or clinical studies. Southeast Asian, Middle Eastern, and Latin American GHWP members may accept CE or FDA data but often require additional evidence of applicability to local populations and environments. Companies need to systematically prepare clinical evaluation documentation based on target market, product risk class, intended use, and existing evidence.

Core questions include: What should the clinical evaluation for a POCT product cover? How can existing data be efficiently reused? How should unique national requirements be addressed? What common mistakes do companies make during preparation? This article provides a practical reference pathway covering registration logic, document preparation points, common errors, and operational checklists.

Registration Judgment Logic

Before preparing clinical evaluation documentation, follow this systematic judgment process:

Step 1: Determine whether the product falls under the target country's medical device regulation.

POCT products are mostly in vitro diagnostic (IVD) reagents or medical devices, but some countries classify certain rapid tests (e.g., blood glucose strips, pregnancy strips) as drugs or health products. For example, the EU IVDR classifies devices into class A/B/C/D, the FDA categorizes CLIA waiver, moderate, or high complexity, and some Southeast Asian countries use risk-based class I/II/III.

Step 2: Determine the risk class and registration pathway.

High-risk products (e.g., infectious disease tests, cardiac markers) usually require full clinical study data. Low-risk products (e.g., urine test strips) may only require analytical performance validation. Registration routes include premarket approval, self-declaration, and notification, depending on the target country.

Step 3: Assess the reusability of existing data.

If the company already holds NMPA (China), CE (EU), FDA (US), or MDSAP certification, clinical data may be reusable under certain conditions. However, differences in ethnicity, epidemiology, operating environment, and sample matrix across countries may make data not directly transferable. For example, clinical performance data from Asian populations may be more acceptable in Southeast Asia, while data from Western populations may require adjustment.

Step 4: Confirm specific requirements for technical files, performance validation, risk management, and clinical evaluation or evidence.

Clinical evaluation documentation should be based on ISO 20916 (IVD clinical performance study standard), ISO 14155 (clinical investigation standard), or target country guidelines (e.g., FDA CLSI guidelines, EU MDCG 2022-2). Prepare analytical performance reports (precision, accuracy, limit of detection, linear range, interfering substances, etc.), clinical performance reports (sensitivity, specificity, positive predictive value, negative predictive value, ROC curve, etc.), and clinical evidence addressing uncertainty in risk analysis.

Step 5: Confirm labeling, local agent, and post-market maintenance requirements.

Since POCT products may be used by non-professionals, labeling must be in the local language and include operating steps, result interpretation, and limitations. Additionally, a local agent or authorized representative must be designated to handle post-market surveillance, adverse event reporting, change notifications, and certificate maintenance.

Data and Evidence

Clinical evaluation documentation for overseas registration of POCT products typically includes the following core elements:

1. Clinical Evaluation Plan (CEP)

Define the evaluation purpose, methodology, data sources, and acceptance criteria. This must align with the intended use, risk class, and regulatory requirements.

2. Analytical Performance Study Data

Include precision (repeatability and reproducibility), accuracy (comparison to a reference method), limit of detection (LoD), limit of quantification (LoQ), linear range, interference substances, cross-reactivity, and carry-over contamination. Data should be generated from at least two independent laboratories, with sample types covering the target population.

3. Clinical Performance Study Data

For qualitative tests, provide clinical sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and agreement with a gold standard (Kappa value). For quantitative tests, provide bias, total allowable error, and analysis using Passing-Bablok or Bland-Altman methods. Sample size must be calculated based on statistical principles and cover different subpopulations (age, sex, race, disease status, etc.).

4. Clinical Trial Report (if applicable)

For high-risk products or when no equivalent device exists, a prospective clinical study must be designed, following ethical and GCP requirements. The report must include the study protocol, subject information, statistical analysis results, and conclusions.

5. Literature Review and Equivalent Device Comparison

When citing published literature or comparing with a marketed device, provide the search strategy, screening criteria, data extraction table, and comparative analysis. The equivalence argument must focus on intended use, analytical principle, sample type, performance indicators, and other key elements.

6. Analysis Linking Clinical Evidence to Intended Use

Explain how clinical data support the intended use claims. For example, a rapid cardiac troponin POCT product must demonstrate clinical decision-making value (e.g., agreement with standard methods and diagnostic performance for suspected myocardial infarction).

7. Clinical Information in Labeling

Include performance summary, limitations, reference intervals, and precautions, all consistent with the clinical evaluation documentation.

Common Errors

• Directly using clinical data from other markets without local assessment. Differences in ethnicity, disease prevalence, and laboratory conditions can lead to performance variability; local validation data are required.
• Inadequate sample size or failure to consider statistical requirements. Many companies conduct clinical studies with only dozens of samples, leading to unreliable results and regulatory scrutiny.
• Failing to distinguish analytical performance from clinical performance. Good analytical performance does not automatically translate into adequate clinical performance; companies often overlook clinical sensitivity and specificity in specific contexts.
• Poorly structured clinical evaluation reports with incomplete evidence chains. For example, not clearly identifying data sources (internal studies, literature, or equivalent devices) or not linking clinical evidence to risk analysis.
• Ignoring operator factors. POCT products are often used by non-professionals, but clinical studies performed under standard laboratory conditions miss real-world performance data.
• Lack of early communication with target country regulators. Companies prepare documents in isolation and only discover non-compliance after submission, causing delays.
• Neglecting post-market clinical follow-up plans. Many countries require a post-market performance follow-up (PMPF) plan, which is often omitted.

Company Preparation Checklist

• Identify target markets and corresponding clinical evaluation guidelines (e.g., EU MDCG, FDA CLSI, China NMPA guidance).
• Establish a cross-functional team including regulatory, R&D, clinical, quality assurance, and the local agent.
• Collect and organize existing clinical data (China, CE, FDA, etc.) and assess applicability.
• Develop a clinical evaluation plan and define the types of supplementary studies and sample sizes required.
• Conduct analytical performance studies covering all required performance indicators and meeting target country standards.
• Conduct clinical performance studies with adequate sample sizes and coverage of target population subgroups.
• Write a clearly structured clinical evaluation report with proper citations, raw data, and statistical analysis results.
• Prepare the clinical performance summary for labeling, including translation and localization.
• Select a local agent or authorized representative and sign an agreement defining responsibilities.
• Establish a post-market performance follow-up plan, including adverse event reporting and periodic updates.
• Conduct an internal audit or pre-submission review to ensure the clinical evaluation documentation is complete and accurate.
• Actively follow up on regulatory feedback after submission and provide supplementary information or clarification promptly.

AIMEILI Regulatory Interpretation and Business Impact

The most common misjudgment when preparing clinical evaluation documentation for overseas registration of POCT products is assuming that existing CE or FDA data can be directly applied to all markets. In reality, significant differences exist across countries in terms of population, environment, sample matrix, and operator requirements. For example, Southeast Asian countries require validation against common local interfering substances (such as malaria and Mycobacterium tuberculosis), while Middle Eastern countries may focus on sample stability under high temperatures. We recommend that companies first conduct a regulatory gap analysis for target markets at the project initiation stage, clarifying which data can be reused and which require local studies.

Second, core clinical evidence (such as analytical performance, clinical sensitivity, and specificity) should be generated from the design phase using globally harmonized standards (e.g., CLSI or ISO) to maximize reuse value. At the same time, companies must recognize the essential role of the local agent—not only as a registration contact but also as the entity responsible for post-market surveillance and certificate control. Many companies suffer registration expiration or revocation due to agent changes or failure to renew certificates, leading to significant losses. For multiple-country registration, we recommend first completing clinical evaluation in one highly demanding market (e.g., EU or US), then using that basis to adjust and supplement for other markets, thereby reducing duplicate work and the risk of deficiencies.

Common Follow-up Questions

Q1: Can clinical evaluation for POCT products rely entirely on literature?

Generally, no. Literature can serve as supporting evidence, but regulators require manufacturers to provide direct performance data on their own product. For low-risk products (e.g., urine strips), if sufficient literature exists and the product is highly similar, partial literature citation may be accepted, but internal validation data are still necessary. High-risk products (e.g., infectious disease tests) require clinical studies.

Q2: How to determine clinical sample size?

Sample size should be calculated using statistical methods, considering expected sensitivity, specificity, confidence interval width, and disease prevalence. For example, for qualitative tests with clinical sensitivity above 95%, a minimum of 100 positive and 100 negative samples is often needed (refer to CLSI EP12 or EP24). Consult a biostatistician or refer to target country guidelines.

Q3: Can clinical evaluation documentation be shared across multiple countries?

Core clinical data (e.g., analytical performance, clinical performance study results) can be shared, but local adaptation is required for each market. For example, reference intervals may differ, and local laboratory-established reference ranges must be provided; some markets require subgroup analysis for local populations. We recommend preparing one core clinical evaluation report and attaching country-specific annexes.

This article is compiled from AIMEILI's registration practice database, medical device international registration knowledge base, and public regulatory information. Specific projects should be based on the latest requirements of the target country regulatory authority and the product's underlying data.